ZOLL Receives FDA Clearance and CE Mark to Expand the Thermogard Platform – All-In-One Core and Surface Cooling

January 8, 2024 |

2 min read

ZOLL ® announced today that it has received FDA clearance and CE mark* for a significant upgrade to the versatility of the Thermogard™ Temperature Management System.

CHELMSFORD, Mass.--(BUSINESS WIRE)--Zoll, LLC^®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it has received FDA clearance and CE mark* for a significant upgrade to the versatility of the Thermogard™ Temperature Management System.

The Thermogard System is now the first and only system to offer the versatility of both core and surface-based temperature management treatment options. The single, streamlined platform now offers solutions for personalized patient care with precise temperature control and intelligent analytics.

“Thermogard with both catheter-based and pad options supports our mission to improve patient outcomes and help save lives,” said Christopher Barnabas, President of ZOLL Circulation. “ZOLL’s Thermogard platform is now the only all-in-one temperature management technology. This novel, one-of-a-kind solution delivers high-quality patient care while supporting hospitals’ evolving treatment protocols and decreasing the workload for nursing staff.”

*The Surface pads and the Surface Start-Up Kit is a self-certified medical device.

About ZOLL

ZOLL, an Asahi Kasei company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and sleep apnea diagnosis and treatment, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, as well as lay rescuers, improve patient outcomes in critical cardiopulmonary conditions. For more information, visit www.zoll.com.

About Asahi Kasei

The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber businesses, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 48,000 employees worldwide, the company contributes to a sustainable society by providing solutions to the world’s challenges through its three business sectors of Material, Homes, and Health Care. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, and manufacture of biotherapeutics, as well as pharmaceuticals and diagnostic reagents. For more information, visit www.asahi-kasei.com.

Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon neutral society by 2050. To learn more, visit https://www.asahi-kasei.com/sustainability/.

Copyright © 2024 ZOLL Medical Corporation. All rights reserved. ZOLL and Thermogard are trademarks or registered trademarks of ZOLL Medical Corporation and/or its subsidiaries in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All other trademarks are the property of their respective owners.